UBE2V2 (ubiquitin conjugating enzyme E2 V2) is a non-canonical ubiquitin-conjugating enzyme that functions as part of the UBE2V2/UBE2N heterodimer to catalyze K63-linked polyubiquitination 1. Unlike typical ubiquitination, this K63-linked chain formation does not target proteins for proteasomal degradation but instead mediates DNA damage tolerance and error-free DNA repair 2. The enzyme plays important roles in cell cycle progression and transcriptional activation of target genes. In cancer biology, UBE2V2 emerges as a significant oncogenic factor. In lung adenocarcinoma, elevated UBE2V2 expression correlates with poor patient survival and is positively associated with PD-L1 expression and cell cycle regulatory proteins 34. UBE2V2 knockdown reduces cancer cell migration through epithelial-mesenchymal transition (EMT) regulation and increases apoptosis while inducing G1 cell cycle arrest 4. Similarly, in prostate cancer, miR-499a suppresses cancer cell proliferation by targeting UBE2V2 5. Beyond cancer, UBE2V2 is implicated in inflammatory responses and tissue homeostasis. In ischemic stroke, UBE2V2 serves as a target of miR-193a-5p, and its modulation influences neutrophil phenotype and neuroprotection 6. Additionally, UBE2V2 accumulation contributes to trophoblast apoptosis in severe preeclampsia through PSME3-mediated degradation pathways 7. These findings position UBE2V2 as a potential therapeutic target across multiple pathological conditions.